RecruitingNCT07282015
Real-world Secukinumab Outcomes in Canadian HS Patients
A Prospective Study to Describe the Real-world Treatment Outcomes in Canadian Patients With Moderate-to-severe Hidradenitis Suppurativa Treated With secukInumab (HS-RISE)
Sponsor
Novartis Pharmaceuticals
Enrollment
142 participants
Start Date
Dec 12, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
The HS-RISE study aims to assess real-world HS treatment outcomes and patterns, safety of secukinumab, and to describe the baseline characteristics of patients diagnosed with moderate-to- severe HS who are prescribed secukinumab in Canadian routine clinical practice.
Eligibility
Min Age: 18 YearsMax Age: 100 Years
Inclusion Criteria5
- Patients must give written, signed, and dated informed consent before any information is collected and any study-related activity is performed.
- Adult patients at the time of informed consent signature.
- Patients with the diagnosis of moderate-to-severe HS, as determined by the dermatologist.
- Patients who have been newly prescribed secukinumab as part of routine clinical care according to the approved Canadian PM. The decision to prescribe secukinumab must be made prior to,and independent of, study participation. First treatment with secukinumab must occur no more than 7 days (≤7 days) prior to Baseline visit.
- Patients who can understand written and spoken Canadian English or French.
Exclusion Criteria3
- Any medical or psychological condition in the treating physician's opinion that may prevent the patient from study participation.
- Patients who have any contraindications to treatment with secukinumab, as defined in the Canadian PM.
- Patients who have had any prior exposure to secukinumab (i.e., >7 days prior to the baseline visit).
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(13)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07282015
Related Trials
Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa
NCT0717091779 locations
A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
NCT0722556963 locations
Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic Inflammatory Skin Diseases
NCT065994111 location
A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa
NCT0692185018 locations
Evaluate the Safety and Efficacy of Subcutaneous Siplizumab in the Treatment of Hidradenitis Suppurativa.
NCT063264761 location